A Traditional Chinese Patent Medicine ZQMT for Neovascular Age-Related Macular Degeneration: a multicenter randomized clinical trial.

CONCLUSION: The combinatory therapy of ranibizumab and traditional Chinese patent medicine ZQMT had equivalent effects on visual acuity improvement and safety profiles as the ranibizumab treatment alone. Ranibizumab injections coupled with ZQMT offer therapeutic advantages in terms of reduction of retinal lesions and eases the financial burden of patients undergoing treatment by reducing the frequency of necessary ranibizumab injections. PMID: 30621562 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30621562?dopt=Abstract

Source: Current Molecular Medicine - January 7, 2019 Category: Molecular Biology Authors: Jin M, Dai H, Zhang X, Wang Y, Han M, Zhang H, Liu Y, Wang Z, Gao X, Li L, Wen X, Liu Y, Wei L, Chen Y Tags: Curr Mol Med Source Type: research